Retatrutide — nicknamed "Triple G" — has posted the largest weight-loss results ever seen from a medication, with about 28% average weight loss in its main phase 3 trial. Dr. Judith Borger breaks down how this investigational triple agonist works on GIP, GLP-1, and glucagon, what the phase 2 and phase 3 studies show, how it compares to semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro), and why the "research peptide" versions sold online are a real risk.
In this episode
How semaglutide and tirzepatide work, and the step from single to dual to triple agonist
Why glucagon is the surprising — and important — third hormone
Results from TRIUMPH-1 through -4 and TRANSCEND-T2D-1
Side effects, including dysesthesia and what it means for your skin
What's still unknown: head-to-head data, heart outcomes, lean mass
Podden och tillhörande omslagsbild på den här sidan tillhör
Judith Borger. Innehållet i podden är skapat av Judith Borger och inte av,
eller tillsammans med, Poddtoppen.
